- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Loading...
A novel interarterial shunt device (IASD) provides sustained clinical benefit and is safe for patients with heart failure and preserved ejection fraction (HFpEF) 1 year after implantation.
These 1-year outcomes were presented at the AHA Scientific Sessions 2016 and published in Circ. Heart Fail.
REDUCE LAP-HF is a multicentre, prospective, nonrandomized, open-label, single-arm study designed to assess the performance and safety of an IASD in patients with symptomatic HFpEF. In
total, 64 patients with left ventricular ejection fraction ≥40%, NYHA class II–IV, and elevated pulmonary capillary wedge pressure (≥15 mmHg at rest or ≥25 mmHg during exercise) were
implanted with an IASD. At 12 months, improvements in quality-of-life score (P
